RCEL
AVITA Medical·NASDAQ
--
--(--)
--
--(--)
5.93 / 10
Netural
Analyst coverage is limited; two analysts show a Strong Buy (66.7%) and Neutral (33.3%) split, with a historical win rate of 42.9% for bullish calls. Fund-flow data show a negative trend at the block and medium levels (inflow ratios ~0.49), yet the overall score of 7.48/10 reflects resilient buying interest. Investors may interpret this as cautious accumulation amid prevailing pessimism.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
67%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-16
InstitutionLake Street
Times predicted2
Historical Win Rate50.0%
What is the analyst consensus for RCEL?
- RCEL holds a Bearish analyst rating, with 67% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.93/10 (Netural).
